ENDRA Life Sciences (NASDAQ:NDRA) Stock Price Down 3.5% – Should You Sell?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) shares fell 3.5% during trading on Tuesday . The company traded as low as $4.96 and last traded at $4.99. 12,031 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 798,885 shares. The stock had previously closed at $5.17.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on NDRA. Wall Street Zen downgraded ENDRA Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. Weiss Ratings restated a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $50.00.

ENDRA Life Sciences Trading Down 3.5%

The company has a market cap of $3.74 million, a price-to-earnings ratio of -0.15 and a beta of -0.09. The business has a fifty day moving average of $5.27 and a two-hundred day moving average of $4.83.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings results on Thursday, August 14th. The company reported ($1.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.27) by $0.56. On average, research analysts forecast that ENDRA Life Sciences Inc. will post -47.46 EPS for the current fiscal year.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.